Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
 

Life Sciences

full industries list
Life Sciences Image
News
Events
Litigation Blog
Hatch-Waxman

Fish attorneys have served as leading advisors to pioneers in the pharmaceutical, biotechnology, and life sciences fields for more than a century. For three consecutive years, we have been named the top US law firm for life sciences and biotechnology IP work by Managing Intellectual Property magazine. Clients choose Fish because of the technical and scientific expertise of our internationally recognized attorneys.

Large and small companies, along with academic and research institutions, turn to Fish’s team to protect their most valuable innovations. We offer biotechnology and pharmaceutical clients services that include:

  • Patent portfolio planning, strategic advice, opinions, and prosecution
  • Post-grant proceedings at the USPTO
  • Litigation services, including representation in Hatch-Waxman cases
  • FDA expertise
  • Counsel on licensing and other transactions

We have a rapidly expanding practice representing branded pharmaceutical companies in Hatch-Waxman litigation. Biotechnology and pharmaceutical companies trust Fish’s litigation team to handle these complicated, high-stakes cases because we are the world’s most experienced patent litigators.

Examples of our biotechnology and pharmaceutical work include:

  • Representing dozens of biotechnology and pharmaceutical clients in patent infringement litigation
  • Successfully litigating ANDA cases on behalf of branded pharmaceuticals
  • Obtaining patents for therapeutic agents and methods currently in clinical trials, including tumor-specific agents such as oncolytics viruses and humanized antibodies and methods for treating strokes
  • Patenting groundbreaking tissue engineering patents on breakthroughs that show promise in treating spinal cord injuries
  • Obtaining the first patent on a genetically engineered animal
  • Gaining FDA approvals for small molecule drugs and biologics, including gene and cell therapies, antibiotics, immunologics, and anti-anxiety medications
  • Conducting intellectual property due diligence on thousands of licensing agreements for the merger of two large pharmaceuticals companies in just a few months’ time

Featured Video
A Conversation with Life Science Litigator Jonathan Singer

Featured Video
Principal, Gwilym Attwell Discusses Life Science Intellectual Property

Search Fish Team

Search by Letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
No matches
Life Sciences

Life Sciences Team

What's Trending in Life Sciences

Filter by
News
November 21, 2016
Fish & Richardson Announces Six Principals Named 2016 “Life Science Stars” by LMG Life Sciences
Press Releases
Fish Patent Blog
November 1, 2016
Kyle Bass is on a Roll: Four More Wins at the PTAB
Kyle Bass is on a Roll: Four More Wins at the PTAB
Authors: Tucker N. Terhufen, Tasha M. Francis, Ph.D.
Fish Patent Blog
October 25, 2016
Kyle Bass Wins at the PTAB
Kyle Bass Wins at the PTAB
Authors: Tucker N. Terhufen, Tasha M. Francis, Ph.D.
News
October 20, 2016
Daily Journal Names Fish & Richardson Principal Juanita Brooks to Top 100 List
Press Releases
Media Coverage
Event
April 2nd, 2017
Patent Resources Group (PRG): Pharma and Biotech Patents: A Hatch-Waxman and BPCIA (Biosimilars) Immersion Course Encompassing Prosecution Strategies, FDA Regulation, Post-Grant Challenge, and Litigation
Patent Resources Group (PRG): Pharma and Biotech Patents: A Hatch-Waxman and BPCIA (Biosimilars) Immersion Course Encompassing Prosecution Strategies, FDA Regulation, Post-Grant Challenge, and Litigation
Speaking Engagement
News
September 14, 2016
An End-Run Around Myriad And 'Product Of Nature' Problem
Articles
News
July 1, 2016
Fish & Richardson Named One of 24 Most Loved Law Firms by General Counsel; One of 10 Firms GCs Love for Pharma Work
Press Releases
Fish Patent Blog
June 30, 2016
Remedy to Incentivize Innovation as In Vitro Diagnostics Face Patent-Eligibility Challenges and Added Regulatory Scrutiny
Remedy to Incentivize Innovation as In Vitro Diagnostics Face Patent-Eligibility Challenges and Added Regulatory Scrutiny
Authors: Gina Nellesen, Terry G. Mahn
News
June 30, 2016
Biologic Patents Are Under Attack
Articles
News
June 29, 2016
Fish Receives Top Tier 1 National Rankings in Patent Prosecution and Patent Litigation from The Legal 500
Press Releases
News
June 8, 2016
Fish Receives Top “Band 1” National Rankings for Intellectual Property and ITC Practices in Chambers USA 2016
Press Releases
News
June 7, 2016
Fish & Richardson Obtains Reversal of $200 Million Patent Verdict Against Gilead After Merck’s “Pervasive Pattern of Misconduct”
Press Release
load more topics